Topspin Partners

Mission Product Holdings, Inc. manufactures, markets, and distributes athletic and performance apparel and accessories for men and women. The company offers t-shirts, tank tops, jackets, vests, shorts, socks, leggings, cooling towels, and head bands. It provides temperature control products under HydroActive MAX, RadiantActive, and Vaporactive brand names. Additionally, the company offers its products through online retail. Mission Product Holdings, Inc. was incorporated in 2007 and is headquartered in New York, New York.

reCommerce Brands operates as an e-commerce platform for Amazon brand products. Its services include creative services, brand protection, brand optimization, streamlined distribution, and data reporting. The company was founded in 2013 and is based in Deerfield Beach, Florida.

Codagenix, Inc. is a biotechnology company focused on developing live-attenuated viral vaccines for various viral infections, including influenza, dengue, respiratory syncytial virus, and polio. Established in 2009 and located in Farmingdale, New York, the company leverages its Synthetic Attenuated Virus Engineering (SAVE) platform, which utilizes computer-based rational design to engineer viral genomes for vaccine development. This innovative approach allows for the creation of vaccine strains that effectively deliver target antigens through a modified viral backbone. In addition to human vaccines, Codagenix also offers solutions for agricultural and companion animal vaccines. The company has been involved in the development of a COVID-19 vaccine, further expanding its portfolio in response to emerging health challenges.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Japonesque LLC, established in 1984 and headquartered in San Ramon, California, specializes in beauty care products aimed at makeup artists and beauty professionals. The company offers a diverse range of items, including cosmetics, makeup brushes, eyelash curlers, nail clippers, and skincare products. Drawing inspiration from the professional makeup tools used in Kabuki theater, Japonesque combines high-impact color and long-wear textures in its offerings, which cater to discerning makeup enthusiasts. Its products are available through various retailers in the United States and internationally via beauty supply stores, salons, and spas. With nearly four decades of expertise, Japonesque continues to provide essential beauty tools and accessories that reflect the artistry and innovation of the beauty industry.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for patients suffering from debilitating inflammatory diseases such as Crohn's Disease and rheumatoid arthritis. Founded in 2006, the company utilizes a proprietary approach based on the Inflammatory Reflex, a natural mechanism by which the central nervous system modulates the immune system. This mechanism, discovered by co-founder Kevin Tracey, has been extensively documented in scientific literature. SetPoint's innovative microregulator aims to enhance the body's natural response to inflammation, providing therapy that offers comparable anti-inflammatory effects to leading pharmaceuticals but with potentially lower costs and improved safety. The company is currently conducting human clinical trials for its devices in rheumatoid arthritis across four centers in Europe.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.

Celmatix is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead program in ovarian senescence and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, focused on developing innovative medicines for cancer and other serious conditions. The company's lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, Peloton is exploring PT2977 in various other indications, including von Hippel-Lindau disease-associated renal cell carcinoma and glioblastoma multiforme, as well as in combination therapies for metastatic renal cell carcinoma. Furthermore, Peloton is developing PT2567, another oral HIF-2a inhibitor in preclinical stages aimed at non-oncology applications, notably pulmonary arterial hypertension. Founded in 2010 and initially known as Damascus Pharmaceutics, Peloton Therapeutics has formed strong partnerships with academic institutions and secured funding from organizations like the Cancer Prevention Research Institute of Texas, positioning itself as a key player in the biotech sector.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.

Remedy Health Media is an operator of a digital health platform intended to provide health-related information that produces, publishes, and distributes health magazines to consumers and caregivers. It offers content, tools, and real stories related to consumer health and wellness through the development of authentic communities of health information seekers who can interact and learn from a relatable physician, pharmacist, public health, and patient experts that enable the customers to make informed choices about their health and well-being. The company's mission is to empower patients and caregivers with the information and applications needed to efficiently navigate the healthcare landscape and as a result, to permit better health outcomes through the use of its products and services. Remedy Health Media was established in 1994 and is headquartered in New York.

Bear Down Brands is a network of consumer brands that each focus on premium home, health, and personal care products.Bear Down Brands mission is to create elegant, practical, and innovative products that enhance the way you care for yourself and the world around you.Bear Down's focus has been on developing a well-rounded product portfolio while providing advanced product technologies, award-winning customer support, and strong brand relationships with our consumers.

Codagenix, Inc. is a biotechnology company focused on developing live-attenuated viral vaccines for various viral infections, including influenza, dengue, respiratory syncytial virus, and polio. Established in 2009 and located in Farmingdale, New York, the company leverages its Synthetic Attenuated Virus Engineering (SAVE) platform, which utilizes computer-based rational design to engineer viral genomes for vaccine development. This innovative approach allows for the creation of vaccine strains that effectively deliver target antigens through a modified viral backbone. In addition to human vaccines, Codagenix also offers solutions for agricultural and companion animal vaccines. The company has been involved in the development of a COVID-19 vaccine, further expanding its portfolio in response to emerging health challenges.

Pure Enrichment is the manufacturer of premium home, health, and personal care products.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for patients suffering from debilitating inflammatory diseases such as Crohn's Disease and rheumatoid arthritis. Founded in 2006, the company utilizes a proprietary approach based on the Inflammatory Reflex, a natural mechanism by which the central nervous system modulates the immune system. This mechanism, discovered by co-founder Kevin Tracey, has been extensively documented in scientific literature. SetPoint's innovative microregulator aims to enhance the body's natural response to inflammation, providing therapy that offers comparable anti-inflammatory effects to leading pharmaceuticals but with potentially lower costs and improved safety. The company is currently conducting human clinical trials for its devices in rheumatoid arthritis across four centers in Europe.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Palmetto Moon, LLC is a retail company based in Charleston, South Carolina, specializing in apparel, footwear, and gifts for men, women, and children. Founded in 2002, it offers a wide range of products, including T-shirts, jackets, dresses, accessories, and footwear such as sandals and boots. The company emphasizes collegiate, coastal, and southern living in its product offerings, which also include home goods like blankets, décor, and outdoor gear. Palmetto Moon operates multiple store locations throughout the southeastern United States, including cities in North Carolina and South Carolina, and provides an online shopping platform to reach a broader customer base.

Texas Family Fitness, LLC operates a network of health and fitness clubs across Texas, with locations in Coppell, The Colony, Frisco, Plano, and Allen. The company provides a family-friendly environment featuring state-of-the-art equipment and a variety of fitness options, including cardio, dance, yoga, and strength training classes. Personal training services are also available at an affordable monthly rate. By focusing on a family-oriented approach, Texas Family Fitness aims to create a healthy atmosphere for all members while maintaining competitive pricing that offers better value than local competitors.

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.

Polder Housewares designs, markets, and distributes houseware products to its clients.

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

JD Beauty Group is the perfect company to ensure that you are on the top of your beauty products game. Their product quality, selection, diversity, and prices are the best in the industry. They are commited to using only the best materials in concert with the finest craftsmanship.

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.

ThermoLift, Inc. specializes in the development and manufacturing of innovative air conditioning and heat pump systems for both heating and cooling, as well as hot water applications. Established in 2012 and located in Stony Brook, New York, the company targets both residential and commercial markets. ThermoLift is focused on creating a transformative thermally driven heat pump that integrates heating, cooling, and hot water functions into a single device. This technology aims to significantly reduce energy consumption for space conditioning by up to 50%, reflecting the company's commitment to energy efficiency and sustainability.

SynchroPET Inc. provides adaptable and multiuse PET imaging systems. It offers PET/MRI, which provides accessible functionalities for exhaustive preclinical research; Mini-PET, a labtop PET imaging device that is easily moved to different stations within the laboratory; RatCAP, an “O” buoyance traveler that does not impede the animal’s movement; and Wrist PET Detector, a non-invasive PET scanner that circles the wrist for clinical applications. The company was founded in 2013 and is based in Stony Brook, New York.

Codagenix, Inc. is a biotechnology company focused on developing live-attenuated viral vaccines for various viral infections, including influenza, dengue, respiratory syncytial virus, and polio. Established in 2009 and located in Farmingdale, New York, the company leverages its Synthetic Attenuated Virus Engineering (SAVE) platform, which utilizes computer-based rational design to engineer viral genomes for vaccine development. This innovative approach allows for the creation of vaccine strains that effectively deliver target antigens through a modified viral backbone. In addition to human vaccines, Codagenix also offers solutions for agricultural and companion animal vaccines. The company has been involved in the development of a COVID-19 vaccine, further expanding its portfolio in response to emerging health challenges.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics to address cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company leverages insights from human clinical and genetic data to create innovative therapies, particularly targeting conditions like type 2 diabetes and non-alcoholic steatohepatitis (NASH). Key product candidates include Aldafermin, currently in Phase 2b trials for NASH, and NGM313, an antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates under development aim to tackle a variety of health issues, including metabolic syndrome and cancer-related conditions. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and product development efforts. Established in 2007 and based in South San Francisco, California, the company is committed to translating complex biological insights into meaningful medical advances.

PlayMonster is a leading designer, manufacturer and marketer of games, children’s puzzles, preschool toys, creative activities and teaching tools, with focus on innovation and growth of brands and categories.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for patients suffering from debilitating inflammatory diseases such as Crohn's Disease and rheumatoid arthritis. Founded in 2006, the company utilizes a proprietary approach based on the Inflammatory Reflex, a natural mechanism by which the central nervous system modulates the immune system. This mechanism, discovered by co-founder Kevin Tracey, has been extensively documented in scientific literature. SetPoint's innovative microregulator aims to enhance the body's natural response to inflammation, providing therapy that offers comparable anti-inflammatory effects to leading pharmaceuticals but with potentially lower costs and improved safety. The company is currently conducting human clinical trials for its devices in rheumatoid arthritis across four centers in Europe.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics to address cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company leverages insights from human clinical and genetic data to create innovative therapies, particularly targeting conditions like type 2 diabetes and non-alcoholic steatohepatitis (NASH). Key product candidates include Aldafermin, currently in Phase 2b trials for NASH, and NGM313, an antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates under development aim to tackle a variety of health issues, including metabolic syndrome and cancer-related conditions. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and product development efforts. Established in 2007 and based in South San Francisco, California, the company is committed to translating complex biological insights into meaningful medical advances.

Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.

Celmatix is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead program in ovarian senescence and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health.

Celmatix is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead program in ovarian senescence and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health.

Passport Systems, Inc. develops and manufactures cargo screening systems for detection and identification of materials at air and sea ports, border crossings, and other key points in the supply chain industry. Its products are used to identify the contents of a container, including commercial items, contraband, fissile materials, explosives, and various other materials. The company was founded in 2002 and is based in Billerica, Massachusetts.

Neopolitan Networks, headquartered in Palo Alto, California, serves a broad clientele of small, medium-sized, and large organizations with scalable, flexible, robust networking solutions. They provide organizations with transport, including end-to-end private network solutions, Internet connectivity and robust points-of-presence in our data centers that capitalize on advances in fiber optic and wireless technologies to increase network performance and coverage.

Pionetics Corporation specializes in manufacturing innovative water treatment products designed to produce safe and great-tasting drinking water while minimizing wastewater compared to traditional systems. Founded in 1995 and headquartered in San Carlos, California, the company offers a range of products, including water filters, drinking water systems, and water coolers, which cater to household, commercial, and industrial applications. Pionetics also provides installation services and rental options for its water treatment systems. Its products are distributed through authorized dealers both domestically and internationally. The company operates as a subsidiary of Rayne Corporation and is supported by financial backing from Kline Hawkes & Co, NGEN Partners, and Unilever Technology Ventures Fund.

Passport Systems, Inc. develops and manufactures cargo screening systems for detection and identification of materials at air and sea ports, border crossings, and other key points in the supply chain industry. Its products are used to identify the contents of a container, including commercial items, contraband, fissile materials, explosives, and various other materials. The company was founded in 2002 and is based in Billerica, Massachusetts.

Game Trust, Inc. specializes in providing infrastructure for community and commerce applications within the online games and entertainment sector. Founded in 2002 and headquartered in New York, the company develops the Game Frame platform, which offers online casual games and entertainment solutions. This platform is licensed by website operators and game developers, enabling them to enhance user experiences through integrated community features and commerce capabilities in both new and existing titles. Game Trust serves a diverse clientele, including game distributors and developers, and has operations in the United States and Europe. As of October 2007, the company operates as a subsidiary of RealNetworks, Inc.

Sensicore, Inc. develops smart sensor systems and sensor networks that automate water testing, data collection, and analysis for drinking and industrial applications. It offers WaterPOINT, a handheld screening tool and water tester that provides a profile of various chemistry measurements, allowing users to conduct various tests at sites, as well as allows municipalities to manage resources; and WaterNOW, a Web-based data visualization, analysis, and decision support system that enable users to manage water system and data collected by WaterPOINT and other sources. The company also provides sensor kits and bundles, which include disinfection and disinfection/DPD chlorine drinking water test kits, and basic water test kits; and colorimetric test kits, including aluminum, bromine, chloride, copper, cyanide, fluoride, iron, manganese, molybdate, nitrate, nitrite, ortho-phosphate, silica, sulfate, sulfide, and zinc vacuum ampoules. In addition, the company offers accessories, such as portable thermal printers, communications cables, power inverters, and power supply products. It offers products for measuring and monitoring water quality, including incoming water quality and boiler feed monitoring; cooling tower monitoring and process control; filtration system performance monitoring; cleaning and rinse control system monitoring; product testing and control; and food and beverage applications. The company was founded in 2000 and is based in Ann Arbor, Michigan. As of March 31, 2008, Sensicore, Inc. operates as a subsidiary of GE Analytical Instruments, Inc.

Arginox Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies. It offers Tilarginine Acetate Injection that inhibits the production of nitric oxide, which is used for treatment of cardiogenic shocks. Arginox Pharmaceuticals is based in Redwood City, California.

Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Arginox Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies. It offers Tilarginine Acetate Injection that inhibits the production of nitric oxide, which is used for treatment of cardiogenic shocks. Arginox Pharmaceuticals is based in Redwood City, California.

Game Trust, Inc. specializes in providing infrastructure for community and commerce applications within the online games and entertainment sector. Founded in 2002 and headquartered in New York, the company develops the Game Frame platform, which offers online casual games and entertainment solutions. This platform is licensed by website operators and game developers, enabling them to enhance user experiences through integrated community features and commerce capabilities in both new and existing titles. Game Trust serves a diverse clientele, including game distributors and developers, and has operations in the United States and Europe. As of October 2007, the company operates as a subsidiary of RealNetworks, Inc.

netomat, Inc. develops Websites, applications, and social media services that work across desktop, tablet, and mobile devices. It offers mobile solutions, such as mobile Website or responsive design, mobile apps, and location-based services; and Web solutions, which include Websites and microsites Web apps, HTML5/CSS3, HTML email and responsive email, and Web forms and data collection solutions. The company also provides social media solutions, including integration with social media sites and networks, social Web apps and widgets, and social media analytics; and contests, sweepstakes, quizzes, and polls. In addition, it offers creative services, such as Web UI/UX design, mobile UI/UX design, and social campaigns and marketing programs; managed services, which include cloud hosting services, search engine optimization, mobile and Web analytics, Ad integration, and e-commerce integration services; optimization solutions for touch-screen devices; and netomat Mobility Server, which enables organizations to publish Websites across various mobile device models. Further, the company provides netomat MediaHub that enables enterprises to acquire, transform, manage, and stream videos across mobile and desktop devices. It serves tourism organizations, sports leagues, gaming companies, NFL teams, record labels, and law firms in the United States and internationally. netomat, Inc. was founded in 2001 and is based in New York, New York.

comScore, Inc. is an information and analytics company that specializes in measuring audiences, consumer behavior, and advertising across various media platforms globally. The company provides a range of products and services, including Media Metrix and Mobile Metrix for website and app measurement, Video Metrix for digital video consumption metrics, and Plan Metrix for insights into consumer lifestyles. Additionally, it offers validated Campaign Essentials, which ensure the visibility and safety of digital ad impressions, and Campaign Ratings for comprehensive campaign evaluation across media. Its services extend to TV Essentials, StationView Essentials, and OnDemand Essentials, integrating traditional TV viewership with digital data. Furthermore, comScore delivers analytics for the film industry, capturing real-time box office results and audience insights. Founded in 1999 and headquartered in Reston, Virginia, comScore serves over 3,200 clients across more than 75 countries, focusing on delivering precise, cross-platform measurement solutions for the evolving media landscape.

Sensicore, Inc. develops smart sensor systems and sensor networks that automate water testing, data collection, and analysis for drinking and industrial applications. It offers WaterPOINT, a handheld screening tool and water tester that provides a profile of various chemistry measurements, allowing users to conduct various tests at sites, as well as allows municipalities to manage resources; and WaterNOW, a Web-based data visualization, analysis, and decision support system that enable users to manage water system and data collected by WaterPOINT and other sources. The company also provides sensor kits and bundles, which include disinfection and disinfection/DPD chlorine drinking water test kits, and basic water test kits; and colorimetric test kits, including aluminum, bromine, chloride, copper, cyanide, fluoride, iron, manganese, molybdate, nitrate, nitrite, ortho-phosphate, silica, sulfate, sulfide, and zinc vacuum ampoules. In addition, the company offers accessories, such as portable thermal printers, communications cables, power inverters, and power supply products. It offers products for measuring and monitoring water quality, including incoming water quality and boiler feed monitoring; cooling tower monitoring and process control; filtration system performance monitoring; cleaning and rinse control system monitoring; product testing and control; and food and beverage applications. The company was founded in 2000 and is based in Ann Arbor, Michigan. As of March 31, 2008, Sensicore, Inc. operates as a subsidiary of GE Analytical Instruments, Inc.

Pionetics Corporation specializes in manufacturing innovative water treatment products designed to produce safe and great-tasting drinking water while minimizing wastewater compared to traditional systems. Founded in 1995 and headquartered in San Carlos, California, the company offers a range of products, including water filters, drinking water systems, and water coolers, which cater to household, commercial, and industrial applications. Pionetics also provides installation services and rental options for its water treatment systems. Its products are distributed through authorized dealers both domestically and internationally. The company operates as a subsidiary of Rayne Corporation and is supported by financial backing from Kline Hawkes & Co, NGEN Partners, and Unilever Technology Ventures Fund.

comScore, Inc. is an information and analytics company that specializes in measuring audiences, consumer behavior, and advertising across various media platforms globally. The company provides a range of products and services, including Media Metrix and Mobile Metrix for website and app measurement, Video Metrix for digital video consumption metrics, and Plan Metrix for insights into consumer lifestyles. Additionally, it offers validated Campaign Essentials, which ensure the visibility and safety of digital ad impressions, and Campaign Ratings for comprehensive campaign evaluation across media. Its services extend to TV Essentials, StationView Essentials, and OnDemand Essentials, integrating traditional TV viewership with digital data. Furthermore, comScore delivers analytics for the film industry, capturing real-time box office results and audience insights. Founded in 1999 and headquartered in Reston, Virginia, comScore serves over 3,200 clients across more than 75 countries, focusing on delivering precise, cross-platform measurement solutions for the evolving media landscape.

TeraLogic designs integrated circuits, software and platforms for digital TV.